The influence of sulfonylurea or dipeptidyl-peptidase-4 inhibitor on glucose control and the secretion of glucagon and insulin induced by sodium glucose transporter-2 inhibitor in type2 diabetic patients
Not Applicable
- Conditions
- Type2 diabetes mellitus
- Registration Number
- JPRN-UMIN000022661
- Lead Sponsor
- Chiba Central Medical Center, Diabetes Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
1. Malignancy 2. Renal dysfunction(eGFR<60ml/min) 3. Liver dysfunction(AST>100U/l and/or ALT100>100U/l), except of fatty liver or non-alcoholic steatohepatitis 4. Pregnancy 5. Lactation 6. History of treatment for ischemic heart disease or other severe cardiovascular disease 7. Administration of any drugs affecting plasma glucose concentration
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The alternations in glucose and insulin responses after the intravenous glucose load, HbA1c level and fasting glucagon concentration 3 months after administration of SGLT2i and then 3 months after addition of SU or DPP-4i to SGLT2i.
- Secondary Outcome Measures
Name Time Method